相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer
Yong-Zhi Li et al.
JOURNAL OF CANCER (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies
Franco Ionna et al.
CANCERS (2021)
Long Intergenic Non-Coding RNAs in HNSCC: From Junk DNA to Important Prognostic Factor
Joanna Kozlowska et al.
CANCERS (2021)
PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway
Jing Wang et al.
LIFE SCIENCES (2019)
PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio
Yi-Bo Qiu et al.
SCIENTIFIC REPORTS (2019)
The changing therapeutic landscape of head and neck cancer
John D. Cramer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
Xin Jin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles
Zhuo Fu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II
A. Dietz et al.
ANNALS OF ONCOLOGY (2018)
PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma
Ping Fan et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques
Jonathan E. Leeman et al.
JAMA ONCOLOGY (2017)
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
P. Bossi et al.
ANNALS OF ONCOLOGY (2017)
Repression of PES1 expression inhibits growth of gastric cancer
Jieping Li et al.
TUMOR BIOLOGY (2016)
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2016)
Nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation
Masato Nakaguro et al.
CANCER SCIENCE (2015)
Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis
Zhongdong Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
PES1 Differentially Regulates the Expression of ERα and ERβ in Ovarian Cancer
Jieping Li et al.
IUBMB LIFE (2013)
PES1 promotes breast cancer by differentially regulating ERα and ERβ
Long Cheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Transcriptional Regulation of PES1 Expression by c-Jun in Colon Cancer
Wei Xie et al.
PLOS ONE (2012)
Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes
Ding-Wu Shen et al.
PHARMACOLOGICAL REVIEWS (2012)
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
C. H. Chung et al.
ANNALS OF ONCOLOGY (2010)
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution
DJ Adelstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: A Southwest Oncology Group trial
SG Urba et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Biochemical modulation of cisplatin mechanisms of action:: Enhancement of antitumor activity and circumvention of drug resistance
MA Fuertes et al.
CHEMICAL REVIEWS (2003)